Levin Capital Strategies, L.P. Eye Point Pharmaceuticals, Inc. Transaction History
Levin Capital Strategies, L.P.
- $990 Million
- Q2 2025
A detailed history of Levin Capital Strategies, L.P. transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Levin Capital Strategies, L.P. holds 19,000 shares of EYPT stock, worth $248,140. This represents 0.02% of its overall portfolio holdings.
Number of Shares
19,000
Previous 43,000
55.81%
Holding current value
$248,140
Previous $233,000
23.61%
% of portfolio
0.02%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding EYPT
# of Institutions
160Shares Held
67.1MCall Options Held
214KPut Options Held
994K-
Cormorant Asset Management, LP Boston, MA8.33MShares$109 Million7.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$88.9 Million2.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.8MShares$88.8 Million0.11% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.6MShares$60.1 Million0.09% of portfolio
-
Franklin Resources Inc San Mateo, CA4.3MShares$56.2 Million0.01% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $445M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...